Adaptive Biotechnologies Corporation $ADPT Shares Sold by Calamos Advisors LLC

Calamos Advisors LLC reduced its holdings in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 68.0% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 58,808 shares of the company’s stock after selling 125,216 shares during the quarter. Calamos Advisors LLC’s holdings in Adaptive Biotechnologies were worth $816,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Caitong International Asset Management Co. Ltd bought a new stake in shares of Adaptive Biotechnologies during the 4th quarter valued at about $28,000. EverSource Wealth Advisors LLC lifted its holdings in Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after acquiring an additional 1,565 shares during the last quarter. Assetmark Inc. boosted its stake in Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after acquiring an additional 2,708 shares during the period. T. Rowe Price Investment Management Inc. acquired a new position in Adaptive Biotechnologies in the fourth quarter valued at approximately $51,000. Finally, Strive Financial Group LLC acquired a new position in Adaptive Biotechnologies in the fourth quarter valued at approximately $52,000. 99.17% of the stock is owned by institutional investors and hedge funds.

Adaptive Biotechnologies Stock Down 3.5%

ADPT stock opened at $22.10 on Friday. The company has a 50-day simple moving average of $17.41 and a 200 day simple moving average of $16.17. The company has a market capitalization of $3.54 billion, a P/E ratio of -66.97 and a beta of 2.07. Adaptive Biotechnologies Corporation has a fifty-two week low of $21.46 and a fifty-two week high of $91.20.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The firm had revenue of $70.87 million for the quarter, compared to analysts’ expectations of $61.03 million. During the same quarter last year, the company earned ($0.20) EPS. Adaptive Biotechnologies’s quarterly revenue was up 35.1% on a year-over-year basis. Equities analysts anticipate that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ADPT. Guggenheim increased their price target on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. JPMorgan Chase & Co. reduced their price objective on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. BTIG Research restated a “buy” rating and set a $22.00 price objective on shares of Adaptive Biotechnologies in a research note on Wednesday, June 17th. Morgan Stanley increased their target price on Adaptive Biotechnologies from $18.00 to $20.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 9th. Finally, TD Cowen reiterated a “buy” rating on shares of Adaptive Biotechnologies in a research note on Wednesday. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Adaptive Biotechnologies currently has a consensus rating of “Moderate Buy” and an average price target of $20.83.

Insider Activity at Adaptive Biotechnologies

In related news, insider Francis Lo sold 51,004 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $22.45, for a total transaction of $1,145,039.80. Following the transaction, the insider owned 237,688 shares in the company, valued at $5,336,095.60. This trade represents a 17.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sharon Benzeno sold 154,768 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $21.14, for a total value of $3,271,795.52. Following the sale, the insider directly owned 221,278 shares in the company, valued at approximately $4,677,816.92. The trade was a 41.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 920,545 shares of company stock valued at $18,588,281. Insiders own 5.70% of the company’s stock.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.